Trizytek FDA Approval Status
FDA Approved: No
Brand name: Trizytek
Generic name: liprotamase
Company: Eli Lilly and Company
Treatment for: Pancreatic Exocrine Dysfunction
Trizytek (liprotamase) is a non-porcine derived enzyme replacement therapy in development for patients with pancreatic insufficiency. The FDA issued a complete response letter for liprotamase in April 2011.
Development timeline for Trizytek
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.